Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 1:39 AM
Ignite Modification Date:
2025-12-25 @ 1:39 AM
NCT ID:
NCT07247994
Brief Summary:
screen for neurologic and psychiatric disorders in children and
adolescents with IBD.
Detailed Description:
Neurologic symptoms have a great importance in early diagnosis and
treatment preventing major morbidity and later sequelae, especially if they
precede GI symptoms
The prevalence of neurologic manifestations of IBD varies between 0.2% and
36%. Their pathogenesis of neurologic manifestations in IBD consists of 6
mechanisms: 1.malabsorption and nutritional deficiency 2.metabolic agents
3.infections complicating immune suppression 4.side effects of medications or
iatrogenic as a surgical complication 5.thromboembolism 6.immunological
factors
UC patients are similar to or higher than CD patients in the probability of
neurologic symptoms. Neurologic manifestations and complications include:
headache, dizziness, hypotonia, ADHD, tics, sensory complaints, seizures,
neuropsychiatric disorders, peripherial neuropathy, meningitis, vestibular
dysfunction, idiopathic IC hypertension, cerebral vasculitis, demyelinating
disorders and migraine
Study:
NCT07247994
Study Brief:
Protocol Section:
NCT07247994